MYGN
BEARISH
$4.91
Live
Myriad Genetics, Inc. · NASDAQ
Target $7.78
(+58.5%)
$3.76
52W Range
$8.59
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$459.13M
P/E
N/A
ROE
-23.5%
Profit margin
-41.3%
Debt/Equity
0.33
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MYGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a fundamental collapse in financial health. While the balance sheet remains liquid with a strong current ratio (2.67) and low debt-to-equity (0.33), these are lagging indicators compared to the alarming -20.80% YoY revenue decline and -41.29% profit margin. The stock is in a long-term secular decline, losing over 82% of its value over five years, and current valuation is supported only by asset value (P/B 1.25) rather than earnings power.
Key Strengths
Strong liquidity position with a Current Ratio of 2.67
Low leverage with a Debt/Equity ratio of 0.33
Healthy Gross Margin of 68.06% suggesting strong core product value
Low Price-to-Sales ratio (0.82) indicating potential undervaluation relative to revenue
Recent short-term price stabilization (+7% over the last month)
Key Risks
Critical operational failure indicated by Piotroski F-Score of 1/9
Significant revenue contraction (-20.80% YoY)
Deeply negative profitability with a -41.29% profit margin
Extreme earnings volatility and frequent misses of analyst estimates
Severe long-term price depreciation (-82.9% over 5 years)
AI Fair Value Estimate
Based on comprehensive analysis
$6.1
+24.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
22
Weak
45
30
15
20
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Strong Balance Sheet Liquidity, Long-term Price Collapse
Confidence
90%
Value
45/100
Valuation is based on assets and sales rather than earnings, as the company is currently unprofitable.
Positives
- P/S ratio below 1.0
- P/B ratio of 1.25 is relatively low
Watchpoints
- No Graham Number due to negative earnings
- Forward P/E of 30.29 is high for a shrinking company
Future
30/100
Growth metrics are poor; the company is struggling to maintain its top-line revenue.
Positives
- Recent Q/Q EPS growth shows signs of bottoming
Watchpoints
- YoY Revenue growth is sharply negative (-20.80%)
- Operating margins remain deeply negative
Past
15/100
Historical price performance is catastrophic, reflecting a loss of market confidence.
Positives
- Occasional earnings beats in previous years
Watchpoints
- 5-year return of -82.9%
- Consistent failure to maintain positive net income
Health
20/100
The company has a 'strong' balance sheet but 'weak' operational health.
Positives
- Low Debt/Equity (0.33)
- Strong Quick Ratio (1.65)
Watchpoints
- Piotroski F-Score of 1/9 is a major red flag for financial health
Dividend
0/100
Company is in a growth/recovery phase and cannot support dividends.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$4.91
Analyst Target
$7.78
Upside/Downside
+58.5%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MYGN and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MYGN
Myriad Genetics, Inc.
Primary
|
-82.9% | -78.0% | -39.2% | -37.0% | +7.0% | +3.6% |
|
ASMB
Assembly Biosciences, Inc.
Peer
|
-54.7% | +80.2% | +165.0% | +28.7% | +2.8% | -0.6% |
|
ALT
Altimmune, Inc.
Peer
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
|
BCYC
Bicycle Therapeutics plc
Peer
|
-74.2% | -74.7% | -47.5% | -20.1% | -0.6% | +6.8% |
|
ADCT
ADC Therapeutics SA
Peer
|
-86.0% | +85.4% | +181.5% | -5.0% | -9.1% | -4.3% |
MYG
Myriad Genetics, Inc.
Primary
5Y
-82.9%
3Y
-78.0%
1Y
-39.2%
6M
-37.0%
1M
+7.0%
1W
+3.6%
ASM
Assembly Biosciences, Inc.
Peer
5Y
-54.7%
3Y
+80.2%
1Y
+165.0%
6M
+28.7%
1M
+2.8%
1W
-0.6%
ALT
Altimmune, Inc.
Peer
5Y
-80.3%
3Y
-68.4%
1Y
-32.7%
6M
-3.9%
1M
-24.4%
1W
-1.1%
BCY
Bicycle Therapeutics plc
Peer
5Y
-74.2%
3Y
-74.7%
1Y
-47.5%
6M
-20.1%
1M
-0.6%
1W
+6.8%
ADC
ADC Therapeutics SA
Peer
5Y
-86.0%
3Y
+85.4%
1Y
+181.5%
6M
-5.0%
1M
-9.1%
1W
-4.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
30.29
PEG Ratio
N/A
P/B Ratio
1.25
P/S Ratio
0.82
EV/Revenue
0.55
EV/EBITDA
-2.76
Market Cap
$459.13M
Profitability
Profit margins and return metrics
Profit Margin
-41.29%
Operating Margin
-21.41%
Gross Margin
68.06%
ROE
-23.51%
ROA
-7.65%
Growth
Revenue and earnings growth rates
Revenue Growth
-20.8%
Earnings Growth
N/A
Q/Q Revenue Growth
-0.38%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.33
Low debt
Current Ratio
2.67
Strong
Quick Ratio
1.65
Excellent
Cash/Share
$1.61
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.2B
Gross Margin
70.0%
Op. Margin
-1.4%
Net Margin
-3.8%
Total Assets
$0.7B
Liabilities
$0.3B
Equity
$0.4B
Debt/Equity
0.92x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
43%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-02-23
$0.04
+348.3% surprise
2025-11-03
$-0.29
-36.5% surprise
2025-08-05
$-3.57
-1412.7% surprise
Healthcare Sector Comparison
Comparing MYGN against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-23.51%
This Stock
vs
-101.52%
Sector Avg
-76.8%
(Below Avg)
Profit Margin
-41.29%
This Stock
vs
-12.47%
Sector Avg
+231.2%
(Superior)
Debt to Equity
0.33
This Stock
vs
3.4
Sector Avg
-90.3%
(Less Debt)
Revenue Growth
-20.8%
This Stock
vs
124.21%
Sector Avg
-116.7%
(Slower)
Current Ratio
2.67
This Stock
vs
4.56
Sector Avg
-41.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MYGN
Myriad Genetics, Inc.
|
BEARISH | $459.13M | - | -23.5% | -41.3% | $4.91 | |
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $444.7M | - | -36.9% | -103.6% | $28.11 | Compare |
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 | Compare |
|
BCYC
Bicycle Therapeutics plc
|
BEARISH | $482.11M | - | -34.6% | -% | $6.95 | Compare |
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $482.77M | - | -% | -175.3% | $3.8 | Compare |
MYGN
Myriad Genetics, Inc.
BEARISH
Mkt Cap
$459M
P/E
-
ROE
-23.5%
Price
$4.91
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-12 | FOX JENNIFER LYNNE | Officer | Stock Award | 195,876 | - |
| 2026-03-12 | MUZZEY DALE | Officer | Stock Award | 173,196 | - |
| 2026-03-12 | DONNELLY BRIAN J | Officer | Stock Award | 226,804 | - |
| 2026-03-12 | WHEELER BENJAMIN RICHARD | Chief Financial Officer | Stock Award | 206,186 | - |
| 2026-03-12 | SOLAIMAN SHEREEN | Officer | Stock Award | 173,196 | - |
| 2026-03-12 | VERRATTI MARK S | Chief Operating Officer | Stock Award | 247,423 | - |
| 2026-03-12 | RAHA SAMRAAT S. | Chief Executive Officer | Stock Award | 618,557 | - |
| 2026-03-09 | RAHA SAMRAAT S. | Chief Executive Officer | Purchase | 40,000 | $199,844 |
| 2026-02-27 | PHANSTIEL S LOUISE | Director | Purchase | 104,507 | $494,722 |
| 2026-02-02 | HAAS KEVIN RICHARD | Chief Technology Officer | Stock Award | 23,697 | - |
| 2026-02-02 | MUZZEY DALE | Officer | Stock Award | 23,697 | - |
| 2026-02-02 | WHEELER BENJAMIN RICHARD | Chief Financial Officer | Stock Award | 4,994 | - |
| 2026-02-02 | VERRATTI MARK S | Chief Operating Officer | Stock Award | 32,810 | - |
FOX JENNIFER LYNNE
Officer
2026-03-12
195,876 shares
MUZZEY DALE
Officer
2026-03-12
173,196 shares
DONNELLY BRIAN J
Officer
2026-03-12
226,804 shares
WHEELER BENJAMIN RICHARD
Chief Financial Officer
2026-03-12
206,186 shares
SOLAIMAN SHEREEN
Officer
2026-03-12
173,196 shares
VERRATTI MARK S
Chief Operating Officer
2026-03-12
247,423 shares
RAHA SAMRAAT S.
Chief Executive Officer
2026-03-12
618,557 shares
RAHA SAMRAAT S.
Chief Executive Officer
2026-03-09
40,000 shares
·
$199,844
PHANSTIEL S LOUISE
Director
2026-02-27
104,507 shares
·
$494,722
HAAS KEVIN RICHARD
Chief Technology Officer
2026-02-02
23,697 shares
MUZZEY DALE
Officer
2026-02-02
23,697 shares
WHEELER BENJAMIN RICHARD
Chief Financial Officer
2026-02-02
4,994 shares
VERRATTI MARK S
Chief Operating Officer
2026-02-02
32,810 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
HOLD
10 analysts
UBS
2026-02-24
Neutral
Neutral
Wells Fargo
2026-02-24
Equal-Weight
Equal-Weight
Piper Sandler
2025-11-11
Overweight
Overweight
Wells Fargo
2025-11-05
Equal-Weight
Equal-Weight
TD Cowen
2025-11-04
Hold
Hold
UBS
2025-11-04
Neutral
Neutral
Past News Coverage
Recent headlines mentioning MYGN from our newsroom.
Newest → oldest
No matching news yet.